

# CITATION REPORT

List of articles citing

Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study

DOI: 10.1016/s1470-2045(16)30148-6  
Lancet Oncology, The, 2016, 17, 1240-7.

**Source:** <https://exaly.com/paper-pdf/64414409/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
78	Beyond Epstein-Barr virus: genetic predisposition of natural killer T-cell lymphoma. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 1176-7	21.7	
77	Whole transcriptome analysis reveals dysregulated oncogenic lncRNAs in natural killer/T-cell lymphoma and establishes MIR155HG as a target of PRDM1. <i>Tumor Biology</i> , <b>2017</b> , 39, 1010428317701648	2.9	21
76	Extranodal natural killer/T-cell lymphoma presenting as cavernous sinus syndrome. <i>Molecular and Clinical Oncology</i> , <b>2017</b> , 6, 543-546	1.6	6
75	The most important questions in cancer research and clinical oncology : Question 1. Could the vertical transmission of human papilloma virus (HPV) infection account for the cause, characteristics, and epidemiology of HPV-positive oropharyngeal carcinoma, non-smoking East Asian female lung adenocarcinoma, and/or East Asian triple-negative breast carcinoma?. <i>Chinese Future Directions of Genomics Research in Rheumatic Diseases. Rheumatic Disease Clinics of North America</i> , <b>2017</b> , 43, 481-487		2
74	Distinct subtype distribution and somatic mutation spectrum of lymphomas in East Asia. <i>Current Opinion in Hematology</i> , <b>2017</b> , 24, 367-376	2.4	5
73	CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China. <i>Chinese Journal of Cancer</i> , <b>2017</b> , 36, 43	3.3	5
72	Association between extranodal natural killer/T-cell lymphoma and hepatitis B viral infection: a case-control study. <i>Journal of Cancer</i> , <b>2017</b> , 8, 2676-2683	4.5	5
71	Novel findings from the Asian Lymphoma Study Group: focus on T and NK-cell lymphomas. <i>International Journal of Hematology</i> , <b>2018</b> , 107, 413-419	2.3	6
70	Extranodal natural killer/T-cell lymphoma, nasal type, in Senegal. <i>International Journal of Dermatology</i> , <b>2018</b> , 57, 401-405	1.7	3
69	Immunologic Milieu of Mature T-Cell and NK-Cell Lymphomas-Implications for Therapy. <i>Current Hematologic Malignancy Reports</i> , <b>2018</b> , 13, 37-43	4.4	5
68	Clinicopathological features and EBV infection status of lymphoma in children and adolescents in South China: a retrospective study of 662 cases. <i>Diagnostic Pathology</i> , <b>2018</b> , 13, 17	3	6
67	Genome-Wide Association Studies of Cancer in Diverse Populations. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2018</b> , 27, 405-417	4	31
66	Challenges in Managing EBV-Associated T- and NK-Cell Lymphoproliferative Diseases. <i>Frontiers in Pediatrics</i> , <b>2018</b> , 6, 320	3.4	
65	Whole exome sequencing identifies recessive germline mutations in FAM160A1 in familial NK/T cell lymphoma. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 111	7	4
64	Advances in multiple omics of natural-killer/T cell lymphoma. <i>Journal of Hematology and Oncology</i> , <b>2018</b> , 11, 134	22.4	12
63	The Genomics and Molecular Biology of Natural Killer/T-Cell Lymphoma: Opportunities for Translation. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	19
62			

61 Genetics in Lymphomagenesis. **2018**, 723-753

60 New insights in the pathogenesis of T-cell lymphomas. *Current Opinion in Oncology*, **2018**, 30, 277-284 4.2 16

59 EBV in T-/NK-Cell Tumorigenesis. *Advances in Experimental Medicine and Biology*, **2018**, 1045, 459-475 3.6 31

58 High-Throughput Sequence Analysis of Peripheral T-Cell Lymphomas Indicates Subtype-Specific Viral Gene Expression Patterns and Immune Cell Microenvironments. *MSphere*, **2019**, 4, 5 6

57 Development and Validation of a 9-Gene Prognostic Signature in Patients With Multiple Myeloma. *Frontiers in Oncology*, **2018**, 8, 615 5.3 13

56 Recent advances in the diagnosis and treatment of natural killer/T-cell lymphomas. *Expert Review of Hematology*, **2019**, 12, 927-935 2.8 8

55 Epstein-Barr Virus-Positive Natural Killer/T-Cell Lymphoma. *Frontiers in Oncology*, **2019**, 9, 386 5.3 11

54 The role of HLA variation in lymphoma aetiology and survival. *Journal of Internal Medicine*, **2019**, 286, 154-180 10.8 6

53 NK/T-cell lymphomas. *Best Practice and Research in Clinical Haematology*, **2019**, 32, 253-261 4.2 22

52 What we should know about natural killer/T-cell lymphomas. *Hematological Oncology*, **2019**, 37 Suppl 1, 75-81 1.3 8

51 A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC Network study. *Neuro-Oncology*, **2019**, 21, 1039-1048 1 12

50 Pathogenesis and biomarkers of natural killer T cell lymphoma (NKTL). *Journal of Hematology and Oncology*, **2019**, 12, 28 22.4 19

49 Molecular pathogenic pathways in extranodal NK/T cell lymphoma. *Journal of Hematology and Oncology*, **2019**, 12, 33 22.4 43

48 CD30-positive cutaneous extranodal natural killer/T-cell lymphoma: clinicopathological features and survival outcomes. *International Journal of Dermatology*, **2019**, 58, 688-696 1.7 1

47 Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma. *Leukemia*, **2019**, 33, 1451-1462 10.7 44

46 Gastrointestinal T- and NK-cell lymphomas and indolent lymphoproliferative disorders. *Seminars in Diagnostic Pathology*, **2020**, 37, 11-23 4.3 15

45 Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations. *Lancet Oncology, The*, **2020**, 21, 306-316 21.7 19

44 Genetic susceptibility to natural killer T-cell lymphoma. *Lancet Oncology, The*, **2020**, 21, 196-197 21.7 1

43	Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma. <i>Experimental Hematology and Oncology</i> , <b>2020</b> , 9, 30	7.8	4
42	Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma. <i>Leukemia</i> , <b>2020</b> , 34, 3413-3419	10.7	13
41	Extranodal NK/T-Cell Lymphomas: The Role of Natural Killer Cells and EBV in Lymphomagenesis. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	8
40	Peripheral T cell lymphomas: from the bench to the clinic. <i>Nature Reviews Cancer</i> , <b>2020</b> , 20, 323-342	31.3	29
39	Aberrant CD3-Positive, CD8-Low, CD7-Negative Lymphocytes May Appear During Viral Infections and Mimic Peripheral T-Cell Lymphoma. <i>Diagnostics</i> , <b>2020</b> , 10,	3.8	0
38	Frequent mutations in HLA and related genes in extranodal NK/T cell lymphomas. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 95-103	1.9	3
37	Generation of a uniform thymic malignant lymphoma model with C57BL/6J gene deficient mice.. <i>Journal of Toxicologic Pathology</i> , <b>2022</b> , 35, 25-36	1.4	0
36	Natural Killer/T-cell Lymphomas. <b>2021</b> , 159-173		
35	Mechanisms of T-cell Lymphomagenesis. <b>2021</b> , 9-26		
34	Liquid biopsy in extranodal NK/T-cell lymphoma: a prospective analysis of cell-free DNA genotyping and monitoring. <i>Blood Advances</i> , <b>2021</b> , 5, 2505-2514	7.8	3
33	NK-/T-cell lymphomas. <i>Leukemia</i> , <b>2021</b> , 35, 2460-2468	10.7	7
32	Current Progress in Investigating Mature T- and NK-Cell Lymphoma Gene Aberrations by Next-Generation Sequencing (NGS). <i>Cancer Management and Research</i> , <b>2021</b> , 13, 5275-5286	3.6	1
31	Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. <i>Annals of Hematology</i> , <b>2021</b> , 100, 2529-2539 <sup>3</sup>		3
30	Epstein-Barr Virus-Associated T- and NK-Cell Lymphoproliferative Diseases: A Review of Clinical and Pathological Features. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
29	Diagnostic approach to T- and NK-cell lymphoproliferative disorders in the gastrointestinal tract. <i>Seminars in Diagnostic Pathology</i> , <b>2021</b> , 38, 21-30	4.3	1
28	Interleukin-6 reverses Adriamycin resistance in nasal NK/T-cell lymphoma via downregulation of ABCC4 and inactivation of the JAK2/STAT3/NF-B/P65 pathway. <i>Environmental Toxicology and Pharmacology</i> , <b>2021</b> , 85, 103639	5.8	0
27	Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma. <i>Life</i> , <b>2021</b> , 11,	3	1
26	Genetic profiling and biomarkers in peripheral T-cell lymphomas: current role in the diagnostic work-up. <i>Modern Pathology</i> , <b>2021</b> ,	9.8	1

25	Sinonasal malignancies: incidence and histological distribution in Jamaica, 1973-2007. <i>Cancer Causes and Control</i> , <b>2017</b> , 28, 1219-1225	2.8	4
24	Recurrent PD-L1 Structural Rearrangements in Natural Killer/T Cell Lymphoma Patients with Complete Response to PD-1 Blockade Therapy.		3
23	Epidemiology of Aggressive Lymphomas. <i>Essentials</i> , <b>2019</b> , 3-40	1	
22	Review on natural killer/T-cell lymphoma. <i>Hematological Oncology</i> , <b>2021</b> ,	1.3	1
21	Genome-Wide Profiling of EpsteinBarr Virus (EBV) Isolated from EBV-Related Malignancies.		0
20	[How I diagnose and treat NK/T cell lymphoma]. <i>Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi</i> , <b>2020</b> , 41, 446-450	0.4	
19	Immune dysregulation in extranodal NK/T cell lymphomas: potential roles in pathogenesis and immunotherapy. <i>Blood Research</i> , <b>2021</b> ,	1.4	
18	Recent Advances in the Diagnosis and Treatment of Natural Killer Cell Malignancies.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	1
17	Virus moleculares patogénicas del linfoma T/NK extranodal de tipo nasal asociadas con virus de Epstein Barr: Revisión narrativa. <i>Ciencia, Tecnología Y Salud</i> , <b>2021</b> , 8, 245-259	2	
16	Characterization of the humoral immune response to the EBV proteome in extranodal NK/T-cell lymphoma. <i>Scientific Reports</i> , <b>2021</b> , 11, 23664	4.9	2
15	Image_1.TIF. <b>2019</b> ,		
14	Image_2.TIF. <b>2019</b> ,		
13	Table_1.docx. <b>2019</b> ,		
12	Table_2.docx. <b>2019</b> ,		
11	Table_3.docx. <b>2019</b> ,		
10	Cellular Origins and Pathogenesis of Gastrointestinal NK- and T-Cell Lymphoproliferative Disorders. <i>Cancers</i> , <b>2022</b> , 14, 2483	6.6	0
9	How we treat NK/T-cell lymphomas. <i>Journal of Hematology and Oncology</i> , <b>2022</b> , 15,	22.4	1
8	A genomic-augmented multivariate prognostic model for the survival of Natural-killer/T-cell lymphoma patients from an international cohort. <i>American Journal of Hematology</i> ,	7.1	0

- 7 EBV-associated NK and T-cell lymphoid neoplasms. **2022**, 34, 422-431 ○
- 6 Genomic Profiling for Clinical Decision Making in Lymphoid Neoplasms. 1
- 5 Extranodal natural killer/T-cell lymphoma: an overview on pathology and clinical management. **2022**, ○
- 4 Types of T-cell lymphoma-a cytogenetic perspective. **2022**, 84, 104844 ○
- 3 Mature T-cell and NK-cell lymphomas: updates on molecular genetic features. ○
- 2 Rational Targets of Therapy in Extranodal NK/T-Cell Lymphoma. **2023**, 15, 1366 ○
- 1 Cross-cancer pleiotropic analysis identifies three novel genetic risk loci for colorectal cancer. ○